Compare HIVE & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HIVE | RGNX |
|---|---|---|
| Founded | 1987 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 447.1M | 487.2M |
| IPO Year | 2017 | 2015 |
| Metric | HIVE | RGNX |
|---|---|---|
| Price | $1.17 | $7.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 11 |
| Target Price | $5.17 | ★ $21.40 |
| AVG Volume (30 Days) | ★ 10.2M | 1.1M |
| Earning Date | 11-09-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.08 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $297,791,000.00 | $10,393,000.00 |
| Revenue This Year | $18.39 | N/A |
| Revenue Next Year | $41.62 | $24.01 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 158.32 | 126.48 |
| 52 Week Low | $1.34 | $5.46 |
| 52 Week High | $5.34 | $16.19 |
| Indicator | HIVE | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 22.34 | 45.79 |
| Support Level | N/A | $6.79 |
| Resistance Level | $2.33 | $7.32 |
| Average True Range (ATR) | 0.13 | 0.59 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 1.37 | 19.32 |
HIVE Digital Technologies Ltd is a sustainable-energy-focused digital infrastructure company that provides infrastructure solutions through the operation of Tier-1 and Tier-3 data centers. Its computing power is used for high-performance computing (HPC) and for generating hashrate sold to mining pools for cryptocurrency mining. The Company uses cash flow from its hashrate services business to support the expansion of its AI and HPC operations through its subsidiary. The Company focuses on Canada, Sweden, and Paraguay, where low-cost renewable power supports its operations and expansion. It operates in one segment with two revenue streams: the mining and sale of digital currencies and high-performance computing hosting. The majority of its revenue is generated from Bermuda.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.